Health Care & Life Sciences » Pharmaceuticals | Hutchison China MediTech Ltd.

Hutchison China MediTech Ltd. | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
29,409.60
53,037.30
116,640.00
160,142.30
187,295.30
160,573.20
Cost of Goods Sold (COGS) incl. D&A
14,207.70
35,740.60
72,507.40
115,858.60
136,525.10
107,952.20
Gross Income
15,201.90
17,296.70
44,132.60
44,283.70
50,770.20
52,620.90
SG&A Expense
15,832.10
28,385.90
50,528.10
78,892.00
92,248.80
123,164.40
EBIT
663.40
-
6,395.50
34,608.30
41,478.60
70,543.50
Non Operating Income/Expense
770.30
450.00
120.40
348.30
90.10
1,829.20
Interest Expense
950.00
920.70
919.00
1,208.80
1,129.80
756.70
Pretax Income
554.70
12,120.40
6,898.80
35,096.70
41,571.00
64,987.80
Income Tax
671.70
815.60
1,050.50
3,209.80
2,391.60
2,972.80
Equity in Affiliates
6,997.00
9,219.20
14,774.20
49,095.10
26,131.70
14,499
Consolidated Net Income
5,770.60
3,716.80
6,824.80
10,788.60
17,830.90
53,461.60
Net Income
5,049.60
20,547.70
22,913.90
8,669.70
20,761.40
56,100.80
Net Income After Extraordinaries
5,950.40
21,165.40
22,913.90
8,669.70
20,761.40
56,100.80
Net Income Available to Common
4,149.50
19,930.10
22,913.90
8,669.70
20,761.40
56,100.80
EPS (Basic)
0.08
0.38
0.42
0.15
0.33
0.08
Basic Shares Outstanding
52,051.00
52,563.40
54,659.30
59,715.20
61,717.20
664,263.80
EPS (Diluted)
0.08
0.38
0.42
0.14
0.34
0.08
Diluted Shares Outstanding
52,878.40
52,563.40
54,659.30
59,971.10
61,717.20
664,263.80
EBITDA
47.30
10,343.40
5,100.80
32,899.30
39,476.70
67,851.10
Other Operating Expense
33.30
-
-
-
-
-
Non-Operating Interest Income
288.50
339.50
295.20
372.00
947.30
4,483.30
Minority Interest Expense
721.00
16,830.90
29,738.80
2,118.90
2,930.50
2,639.10

About Hutchison China MediTech

View Profile
Address
Cheung Kong Center
Hong Kong
Hong Kong
Employees -
Website http://www.chi-med.com
Updated 07/08/2019
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.